免疫治疗肺癌诱发甲状腺功能异常的研究进展

Research progress on thyroid dysfunction induced by immunotherapy for lung cancer

免疫检查点抑制剂[主要是程序性死亡-1/程序性死亡配体-1(programmed death-1/programmed death ligand-1,PD-1/PD-L1)抑制剂]已经逐渐成为晚期肺癌最具有前景的治疗手段。但临床医师对于免疫相关不良反应仍缺乏足够认识,免疫相关甲状腺功能异常(immune-related thyroid dysfunction,irTD)作为常见的免疫相关不良反应之一,严重时可能会危及生命。本文从发病率、发病机制、预测生物标志物及治疗等方面对PD-1/PD-L1抑制剂治疗肺癌诱发的甲状腺功能异常进行探讨。

Immune checkpoint inhibitors[mainly programmed death-1/programmed death ligand-1(PD-1/PD-L1)inhibitors]have emerged as the most promising therapy in lung cancer treatment.However,clinicians still lack sufficient knowledge about immune-related adverse events.Immune-related thyroid dysfunction(irTD),one of the common immune-related adverse events,can be life-threatening in severe cases.This article discussed the thyroid dysfunction induced by PD-1/PD-L1 inhibitors in the treatment of lung cancer from the aspects of the incidence,pathogenesis,predictive biomarkers and treatment of irTD.